Actively Recruiting
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Led by Henan Cancer Hospital · Updated on 2025-04-23
30
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.
CONDITIONS
Official Title
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 to 75 years old (including 18 and 75)
- Diagnosed as diffuse large B-cell lymphoma with recurrence or progression of central nervous system disease confirmed by imaging, tissue biopsy pathology, or cerebrospinal fluid flow cytometry
- Secondary central nervous system lymphoma allowed if systemic disease is well controlled
- At least one measurable lesion
- ECOG performance status 0-2 (ECOG 3 due to tumors may be included after full assessment)
- Life expectancy of at least 1 month
- Adequate main organ function
- Negative pregnancy test within 7 days for women of childbearing potential, with contraception during study and for 6 months after
- Signed written informed consent
You will not qualify if you...
- Poor peripheral disease control of secondary central nervous system lymphoma
- Prior use of pemetrexed or orelabrutinib
- Active malignant tumor requiring treatment
- History of other malignant tumors
- Serious surgery or trauma within 2 weeks
- Active tuberculosis
- Serious acute or chronic infection requiring systemic therapy
- Congestive heart failure, uncontrolled coronary disease, arrhythmia, or heart infarction within 6 months
- HIV-positive, AIDS, or untreated active hepatitis
- History of deep vein thrombosis or pulmonary embolism within 12 months
- History of mental illness or drug abuse
- Poor compliance during trial or follow-up
- Allergies to active ingredients, excipients, mouse-derived products, or heterologous proteins in the trial
- Investigator determines participant is unsuitable for the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Actively Recruiting
Research Team
Z
Zhihua Yao, M.D. Ph.D
CONTACT
Y
Yanyan Liu, M.D. Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here